Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinaki Biswas

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
American Journal of Clinical Dermatology|May 22, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE TrialEric L Simpson, Jonathan I Silverberg, Jacob P Thyssen, et al.
Dermatology and Therapy|September 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Eric L Simpson, Jonathan I Silverberg, Bob Geng, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Arthritis and Rheumatism|November 1, 2005
Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgiaSamuel A McLean, David A Williams, Richard E Harris, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 28, 2026
Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 yearsMelinda J Gooderham, Jonathan I Silverberg, Marjolein De Bruin-Weller, et al.
Drug Safety|February 2, 2020
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational DataGerd R Burmester, Jeffrey R Curtis, Huifeng Yun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
American Journal of Clinical Dermatology|August 25, 2023
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2Gil Yosipovitch, Melinda J Gooderham, Sonja Ständer, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
American Journal of Clinical Dermatology|May 22, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE TrialEric L Simpson, Jonathan I Silverberg, Jacob P Thyssen, et al.
Dermatology and Therapy|September 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Eric L Simpson, Jonathan I Silverberg, Bob Geng, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Arthritis and Rheumatism|November 1, 2005
Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgiaSamuel A McLean, David A Williams, Richard E Harris, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 28, 2026
Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 yearsMelinda J Gooderham, Jonathan I Silverberg, Marjolein De Bruin-Weller, et al.
Drug Safety|February 2, 2020
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational DataGerd R Burmester, Jeffrey R Curtis, Huifeng Yun, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
American Journal of Clinical Dermatology|August 25, 2023
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2Gil Yosipovitch, Melinda J Gooderham, Sonja Ständer, et al.
Pageof 6